 |
|
  |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
U.S. Centers for Disease Control and Prevention
• Medical News
Tests Planned for Genetically Engineered TB VaccineJanuary 15, 2004 This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document. GlaxoSmithKline Plc., Europe's leading drug manufacturer, and US biotech firm Corixa Corp. said Wednesday they plan to launch the first human test of a genetically engineered TB vaccine. The vaccine, which contains a fusion of proteins from the bacteria that causes TB, has produced good results in lab animals. Twenty volunteers will be enrolled in the US Phase I trial to assess the product's safety and the immune response it generates. A long-established TB vaccine, BCG, was developed 80 years ago, and some scientists say it is only about 50 percent effective. World Health Organization statistics show that 2 million people die annually from TB; some 8 million become sick from it each year.
Back to other news for January 15, 2004 This article is part of TheBody.com's archive. Because it contains information that may no longer be accurate, this article should only be considered a historical document. Reuters 01.14.2004 This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
|
E-Mail
Printable Single-Page
Glossary
Share
